UBS reiterates Gilead Sciences stock rating on strong Yeztugo sales

Yeztugo monthly sales accelerated (February up 56% MoM) with combined Jan-Feb sales of $100M and implied March scripts around $58M, supporting consensus March revenues near ~$145M. Gilead agreed to acquire Ouro Medicines for up to $2.18B ($1.675B upfront, up to $500M milestones) adding OM336 to its inflammation/immunology pipeline. UBS reiterated Buy with a $175 price target (stock $138.74, ~26% to PT) and several other firms set PTs between $125–$160 (Goldman Neutral at $125), while shares are up ~25% over the past year and gross margin is ~78.8%.

Analysis

Gilead’s launch dynamics create an asymmetric play: durable, less-frequent dosing improves adherence and retention economics but reduces script frequency, concentrating revenue volatility into larger, lumpy prescription events. That favors a company with broad commercial reach and deep payer relationships versus smaller specialty rivals that depend on repeat monthly scripts; expect negotiated net prices and prior‑authorization friction to be the principal gating factors over the next 3–12 months.

The Ouro/OM336 deal is a strategic hedge into immunology that shifts R&D optionality from purely antiviral franchises into higher‑margin, orphan autoimmune niches. Integration and manufacturing for a CD3 engager introduce execution risk and capital allocation tradeoffs: positive clinical reads could re-rate multiple expansion, while delays or CMC hurdles would compress near‑term uplifts and increase leverage on the core launch performance.

Catalysts to watch are monthly script cadence, payer coverage decisions, and early OM336 data — each operates on a different clock (weeks for scripts, months for coverage negotiations, 12–24 months for clinical readouts). Tail risks that could reverse the trend include an unexpected safety signal for the class, a rapid price‑negotiation backlash from large payers, or a measurable overstatement of early capture metrics versus ultimate retail uptake.

Consensus appears to price a smooth scaling of the new product and generous optionality from the acquisition; the contrarian angle is that launch variability and payer complexity will keep upside modest near term while clinical/gearing risk from the deal adds asymmetric downside. That makes a risk‑managed exposure to both commercial execution and clinical milestones the preferred way to play the setup rather than an unhedged directional stake.

Key Decisions for Investors

• Long GILD via 12–18 month LEAPS (10–15% OTM calls) funded by selling near‑term calls to convert into a calendar spread — target asymmetric upside of 25–40% over 12–18 months while funding ~40–60% of premium; max loss is premium paid, roll or hedge if script cadence misses expectations at next two monthly prints.
• Buy GILD stock and collar for 3–6 months: sell a near‑term call (capping short‑term upside) and buy a lower‑strike put to limit downside to ~15–20% while keeping upside participation for clinical/acquisition positives; use this around the next monthly sales release to capture post‑print continuation or cushion drawdowns.
• Pair trade to hedge class/regulatory risk: long GILD equity (or LEAPS) paired with short a small‑cap pure‑play CD3/BCMA bispecific (equal notional) for 6–12 months — this isolates company diversification premium and protects against sector‑wide safety headlines; unwind on positive OM336 readout or if differential commercial metrics widen materially.
• Event‑driven short‑term: establish a small long position ahead of the next two monthly script prints but size it for 10–12% volatility; if capture metrics decelerate, add protective puts or exit to preserve capital — ideal holding window is weeks-to-months around prints, not long term without clarity on payer uptake.